Bayer AG


  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • SAO DESIDERIO, Brazil, Feb 27- Brazilian farmers are battling a voracious caterpillar that likely arrived from Asia, challenging the agricultural superpower's widely touted mastery of tropical farming just as it is on the verge of becoming the world's top soybean producer.

  • NEW YORK/ LONDON, Feb 19- A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck& Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.

  • UPDATE 1-U.S. FDA rejects wider use of Xarelto drug Friday, 14 Feb 2014 | 9:31 AM ET

    NEW YORK, Feb 14- U.S. health regulators have declined to approve proposed wider uses of Bayer AG and Johnson& Johnson's lucrative blood clot preventer Xarelto, the drugmakers said on Friday. An advisory panel to the FDA concluded in January that Xarelto should not be approved to prevent new heart attacks or strokes, a use referred to as secondary prevention.

  • Feb 11- An advisory panel to the U.S. Food and Drug Administration said on Tuesday that available evidence does not prove that the painkiller naproxen, sold under the brand names Aleve and Naprosyn, carries a lower cardiac risk than rival products.

  • Feb 11- An advisory panel to the U.S. Food and Drug Administration voted on Tuesday that there is not enough evidence to show conclusively that the painkiller naproxen carries a lower cardiac risk than other popular products.

  • Regeneron forecasts strong Eylea sales; shares rise Tuesday, 11 Feb 2014 | 7:25 AM ET

    Feb 11- Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7- $1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3 percent before the opening bell. It is marketed by Bayer AG in Europe.

  • *India is biggest source of overseas medicines to U.S. NEW DELHI, Feb 10- The United States will on Monday announce a trade enforcement action linked to India, potentially dealing another blow to bilateral relations damaged in December by the arrest and strip-search of an Indian consul.

  • Feb 7- Merck& Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.

  • Feb 6- Merck& Co has agreed to pay $100 million to settle hundreds of lawsuits accusing the U.S. drugmaker of downplaying serious health risks associated with its NuvaRing contraceptive device, Bloomberg reported on Thursday, citing people familiar with the deal.

  • MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

  • Jan 24- Bristol-Myers Squibb Co on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.

  • "Because antimicrobial drug use in both humans and animals can contribute to the development of antimicrobial resistance, it is important to use these drugs only when medically necessary," the FDA said in a release.

  • *Celgene to take 5 pct stake in OncoMed. *Celgene stock down 1.4 pct. Dec 3- Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.

  • Oh, baby! Confusion over free birth control Wednesday, 20 Nov 2013 | 11:07 AM ET
    Contraceptive pills.

    A majority of women are unaware birth control is available for free from health insurance plans under Obamacare, although that right faces court challenges.

  • Oct 23- Bristol-Myers Squibb Co reported better-than-expected quarterly earnings, fueled by strong sales of cancer and diabetes drugs, but weak demand for its new Eliquis blood clot medicine dampened investor enthusiasm.

  • Oct 21- Regeneron Pharmaceuticals Inc said its drug Eylea improved vision in a late-stage trial far better than standard laser treatment among patients with a common form of vision loss caused by blood clots in secondary veins of the retina.

  • These biotech names are ripe for takeover: Cramer Tuesday, 27 Aug 2013 | 7:19 PM ET

    We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.

  • Amgen to buy Onyx for more than $10 billion Monday, 26 Aug 2013 | 7:51 AM ET

    Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.

  • Bayer CEO: Environment becoming more challenging     Wednesday, 31 Jul 2013 | 5:00 AM ET

    Marijn Dekkers, CEO of drug and chemicals company Bayer, tells CNBC that falling earnings in the material sciences division may make it harder to achieve its earnings goals for the year.

Most Popular Video

Wednesday, 16 Apr 2014 | 10:41 AM ET

CNBC's Dominic Chu digs into the year-to-date S&P performance of the airlines and explains why it has been the lone bright spot for the industrial sector.

Wednesday, 16 Apr 2014 | 4:03 PM ET

Providing instant analysis to Google's quarterly numbers, with Victor Anthony, Topeka Capital Markets; Andrew Stoltmann of Stoltmann Law Offices; CNBC contributor Michael Yoshikami; "Fast Money" trader Tim Seymour; CNBC's Michelle Caruso-Cabrera and Dominic Chu.

Wednesday, 16 Apr 2014 | 12:35 PM ET

Intel CEO Brian Krzanich discusses some signs of stability in enterprise in the mature markets, and whether the emerging markets area steadying as well.